Navigation Links
Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
Date:12/21/2009

http://www.soligenix.com/">www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including SGX201, orBec® and LPM(TM), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's require
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... 2014 Summary Global Markets Direct,s, ,Arbor ... provides an overview of the Arbor Pharmaceuticals, LLC.,s ... provides comprehensive information on the current therapeutic developmental ... analysis at various stages, therapeutics assessment by drug ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals ... VRX) today announced that the company,s Bridgewater, ... from the U.S. Food and Drug Administration (FDA) relating ... records with regards to Sculptra Aesthetic injectable, which was ... Letter pertains to the management of Valeant,s contract manufacturers (rather ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Inc. (OTCQX: DATA), a technology and services company ... trials industry, today announced its participation in the ... will address significant milestones made throughout the pharmaceutical ... technologies are delivering. The EuroMeeting will be held ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... launch of its new formulation of Acetadote ® ... treat acetaminophen poisoning. The proprietary new formulation, which does ... other stabilization or chelating agents, is now stocked at ...
Cached Medicine Technology:DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2New Acetadote® Formulation Now Available in the U.S. 2New Acetadote® Formulation Now Available in the U.S. 3New Acetadote® Formulation Now Available in the U.S. 4
(Date:9/30/2014)... potential for doctors to measure damaging "brain tsunamis" ... moved a step closer to reality, thanks to ... Neuroscience Institute. , The research team, led by ... department of neurosurgery at the UC College of ... spread through an injured brain like tsunami wavescan ...
(Date:9/30/2014)... Sleep apnea is a potential health risk for millions of ... behind the disorder: a "fat" tongue. "This is the ... the tongue of obese patients with obstructive sleep apnea," study ... at the University of Pennsylvania Medical Center, said in a ... findings Oct. 1. Sleep apnea is a common disorder ...
(Date:9/30/2014)... Autism is no stranger to the children of ... is access to clinical services, including reliable diagnosis and ... example, validated for use in Swahili, a major language ... researchers at Brown University and the University of Georgia ... implemented at two sites in the country and found ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... Dynamic health trends, changing consumer ... the Bread Production industry over the past five ... their consumption of a variety of industry goods ... the market for white loaf bread and other ... introducing more nutritious products to attract health-conscious consumers, ...
Breaking Medicine News(10 mins):Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... often forces older adults to give up things ... the ability to exercise and participate in physical ... for Eldercare and Rehabilitation Technology (CERT) are working ... developing and evaluating motion-capture technology that monitors the ...
... than placebo, study finds , , TUESDAY, June 10 (HealthDay News) ... disorder (ADHD) in children, a new study finds. , ... of the American Medical Association , the study compared St. ... 17 and found the herb wasn,t any more effective than ...
... June 10 Sen. Olympia Snowe,(R-ME), member of ... -- S.3101 -- that includes pharmacy-related provisions to ... claims and delay the,implementation of Medicaid reimbursement cuts ... owner of Waltz Pharmacy Inc. in,Camden, ME and ...
... Sen. Gordon Smith,(R-OR), member of the ... includes pharmacy-related provisions to provide prompt,payment of ... delay the,implementation of Medicaid reimbursement cuts for ... National Community Pharmacists,Association (NCPA) past president from ...
... NEW YORK, June 10 Ask any entertainment or ... it,s at. And, while watching,your favorite TV show in ... technology just might., (See video from Siemens ... Biograph HD PET-CT system from Siemens is the world,s ...
... SAN DIEGO and MCLEAN, Va., June 10 SAIC, Inc.,(NYSE: ... William Blair Annual,Growth Stock Conference in Chicago on June 18, ... at 3:10 p.m. Central., A live audio webcast of ... site ( http://investors.saic.com ) and an audio,replay of the event ...
Cached Medicine News:Health News:MU researchers enhancing motion-capture technology to benefit older adults 2Health News:St. John's Wort Doesn't Work for ADHD 2Health News:St. John's Wort Doesn't Work for ADHD 3Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:Oregon Community Pharmacy Owner Thanks Sen. Smith for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:SAIC to Webcast Presentation at William Blair Growth Stock Conference 2
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... of the system is the Nightingale Master Patient ... central monitoring station for the Nightingale Monitoring System. ... Nightingale PPM bedside patient monitors, allowing a clinician ... at once., ,The MPC is a Windows ...
... Signs Monitor 300 Series enhances your productivity ... and after procedures. This easy to use ... readings fast and convenient., ,The Vital ... noninvasive blood pressure monitor with the flexibility ...
... The Welch Allyn Atlas monitor is ... conscious sedation, IV anesthesia procedures, and surgery. ... LED numerics that are visible from across ... to learn how to operate the monitor ...
Medicine Products: